Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05217147
Other study ID # THD-2019-18414
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2018
Est. completion date August 31, 2021

Study information

Verified date January 2022
Source Hacettepe University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study was to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value.


Description:

Although there has been a significant increase in survival in many other cancer types through the years, no significant increase has been achieved in laryngeal SCC survival rates in the last 50 years. Despite the advancements in surgical techniques, organ preservation protocols and multidisciplinary approach, significant amount of patients have been living with morbidity or dying due to recurrence and metastasis. This lack of significant improvement in mortality rates creates the need for reliable and accurate biomarkers in early diagnosis, treatment and follow-up. Considering that the prognosis of two patients at the same clinical stage and treated with the same treatment protocol may differ, it suggests that there may be some differences at the molecular level apart from clinical stages. This study was mainly prepared to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value. To reach these aims, 60 patients who were prospectively and consecutively recruited from those who admitted to Hacettepe University, Department of Otorhinolaryngology, Ankara, Turkey, and were diagnosed with LSCC between May 2018 and February 2020. 20 healthy and age-matched controls were chosen from the hospital staff and relatives of the patients. Serum samples were obtained from all participants at the time of diagnosis, centrifuged and stored at -80 C. ELISA method will be used to analyze the serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin. Data analysis will reveal if there are any association between biomarker candidate molecules and clinical parameters.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date August 31, 2021
Est. primary completion date February 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - 60 male or female patients with a newly diagnosed laryngeal squamous cell carcinoma - Patients without any previous history of laryngeal carcinoma - 20 healthy, age- and sex- matched controls Exclusion Criteria: - Previous history of laryngeal squamous cell carcinoma - Having comorbid systemic diseases like DM, hypertension, cardiologic or rheumatologic diseases - Having malign tumors elsewhere - History of chemotherapy/radiotherapy.

Study Design


Intervention

Other:
Obtaining blood samples
Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.

Locations

Country Name City State
Turkey Hacettepe University Cancer Institute Ankara

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum levels of biomarker candidate molecules Serum levels of:
VEGF in pg/ml
sVEGFR1 in pg/ml
VEGFR2 in pg/ml
IGFBP-3 in pg/ml
angiogenin in pg/ml
and endoglin in pg/ml
will be determined in all participants
Basal
Primary Stage Disease stage as stage as early (I-II) or late (III-IV) Basal
Primary Diagnostic sensitivity and specifity of biomarker candidate molecules Receiver operating characteristic analysis will be performed to determine a significant level of any biomarker candidate molecules for diagnostic sensitivity and sensitivity.
Sensitivity and specifity as percentages (%)
Basal
Primary Tumor grade Tumor grade as poor, moderate or well Basal
Primary Recurrence status Recurrence status as yer or no 18 months after reaching the target patient number
Primary Tumor localization Tumor localization as glottic/supraglottic or transglottic Basal
Primary Treatment modality Treatment modality as surgical, non-surgical or combined Basal
Secondary Survival analysis parameters All the patients were contacted for survival analysis.
Overall and disease-free survival will be measured in months and survival rates will be calculated in percentages (%).
Overall survival and disease-free survival rates will be calculated according to levels of biomarker candidate molecules and assessed for any association with any molecule.
18 months after reaching the target patient number
See also
  Status Clinical Trial Phase
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Completed NCT03292341 - Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients. N/A
Completed NCT03653039 - Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy N/A
Completed NCT05746780 - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Completed NCT01700647 - Breath Testing in Early and Late Larynx Cancer N/A
Completed NCT00600223 - Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches N/A
Completed NCT00169247 - Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Phase 2
Recruiting NCT03759431 - Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer Phase 2
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Recruiting NCT04057209 - VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06086119 - Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
Suspended NCT04368702 - CONFIRM: Magnetic Resonance Guided Radiation Therapy N/A
Active, not recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Completed NCT00158652 - Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Phase 3
Terminated NCT03479463 - Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
Completed NCT03096808 - Adaptive Radiotherapy for Head and Neck Cancer Phase 2
Completed NCT03028766 - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer Phase 1
Completed NCT00359645 - Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Phase 3